Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Dombret H, Gardin C . An update of current treatments for adult acute myeloid leukemia. Blood 2016; 127: 53–61.

    Article  CAS  Google Scholar 

  2. Barrett AJ, Battiwalla M . Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010; 3: 429–441.

    Article  Google Scholar 

  3. Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 2013; 31: 3259–3271.

    Article  Google Scholar 

  4. Sauer T, Silling G, Groth C, Rosenow F, Krug U, Görlich D et al. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. Bone Marrow Transplant 2015; 50: 485–492.

    Article  CAS  Google Scholar 

  5. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

    Article  CAS  Google Scholar 

  6. Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400.

    Article  CAS  Google Scholar 

  7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.

    Article  Google Scholar 

  8. Topalian SL, Drake CG, Pardoll DM . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450–461.

    Article  CAS  Google Scholar 

  9. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 443–445.

    Article  CAS  Google Scholar 

  10. Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 850–852.

    Article  CAS  Google Scholar 

  11. Chan TS, Khong PL, Kwong YL . Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 2016; 95: 1913–1915.

    Article  Google Scholar 

  12. Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant 2016; 51: 1268–1270.

    Article  CAS  Google Scholar 

  13. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139–148.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Stelljes.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albring, J., Inselmann, S., Sauer, T. et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant 52, 317–320 (2017). https://doi.org/10.1038/bmt.2016.274

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.274

This article is cited by

Search

Quick links